I. Background
Restenosis remains the limiting factor of percutaneous transluminal coronary angioplasty (PTCA). [1] [2] [3] Renarrowing of the vessel may occur as a result of vascular recoil, neointimal hyperplasia or negative remodeling (contracture) of the vessel. Clinical trials of a variety of pharmacologic agents [4] [5] [6] [7] have met with little success. Of the mechanical means of angioplasty (atherectomy, laser and stenting) only intracoronary stenting has resulted in superior results to balloon angioplasty. 8, 9, 10, 11 However, as the indications for stenting have broadened the likelihood of restenosis has increased. 12 Longer lesions, smaller vessels, poor run-off, diabetes and other comorbid conditions have been associated with unacceptably high rates of restenosis. The gradual development of the concept that restenosis was the end-result of an uncontrolled proliferation of tissue at the injury site laid the groundwork for radiation being tested in this area. 13, 14, 15, 16 In vitro studies had demonstrated the inhibition of proliferation of arterial smooth muscle cells (SMC's) and fibroblasts as well as decreased collagen synthesis by fibroblasts. 17, 18, 19 The development of the porcine overstretch balloon injury model of restenosis has provided an excellent model in which to evaluate new therapies since as radiation. 20 In this animal model one or more of the coronary vessels are subjected to overstretch balloon injury and at two weeks, four weeks or six months the animal is sacrificed and the vessels harvested. Morphometric or immunohistochemical measurements are then undertaken to assess the efficacy of the intervention on the vascular healing response.
The different radiation techniques to prevent restenosis can be considered within a few broad categories: 1.External techniques and 2. Endovascular techniques. In the endovascular therapies we need to consider both temporary implants (catheter based techniques) and permanent implants (radioactive stents). I have arbitrarily divided the catheter based therapies into beta and gamma systems although they could as easily have been considered as sealed source and non-sealed source therapies.
In the following sections we shall discuss the current status of vascular radiotherapy from both preclinical and clinical perspectives.
II. Preclinical Studies of Coronary Radiotherapy a. External Radiation Studies
The potential advantages of external beam irradiation over endovascular approaches include 1) No additional cath lab time to deliver treatment 2) No costs of disposables such as are associated with the new endovascular delivery systems 3)
Ability to optimize the timing of the treatment in relationship to the intervention 4) The ability to delivery fractionated therapy which may be associated with fewer late effects and 5) The delivery of a much more homogeneous dose to the vessel wall.
The results obtained using external irradiation however have been decidedly mixed. The first study of external radiation in coronary vessels was carried out by Schwartz at the Mayo Clinic who tested doses of 4 and 8 Gy delivered by an orthovoltage unit to stented pig coronary arteries. 21 Morphometric analysis carried out four weeks later revealed poorer results in the irradiated animals compared to the controls with the highest dose group faring the worst. This study has been criticized on the basis of magnitude of vessel injury, the use of orthovoltage x-rays and the relatively low doses of radiation which were tested. Due to marked overexpansion of the stent in this study it might be that there is a continuous injury stimulus and the application of radiation at a single point in time would be relatively ineffective. In addition irradiation of a metallic stent with orthovoltage x-rays is likely to be associated with local areas of high dosage due to electronic disequilibirium. At Emory we circumvented these concerns by using doses of megavoltage x-rays (14 Gy) found effective in endovascular studies following balloon injury. 22, 23 When 14 Gy was administered to the whole heart immediately before, after or 2 days following balloon injury we observed reduced neointima formation compared with controls but the lumens were smaller due to negative remodeling (contracture) of the vessel. Recent studies performed in our laboratories using 21 Gy external after either angioplasty or stenting showed a profound and consistent suppression of neointima formation and maintenance of the lumen area. (Table 1) The lack of benefit seen with 14 Gy external vs 14 Gy endovascular suggest either that large volume irradiation requires larger doses or it is not the minimum dose delivered to the vessel wall which is critical in determining the outcome. Studies of 21 and 14 Gy external radiation treatment have shown focal myocardial necrosis, an observation, which we never made with endovascular irradiation at any dose. To reduce the likelihood of significant effects on the myocardium from even higher doses of external radiation therapy (21 Gy) will require very sophisticated treatment techniques. Whether conformal therapies can be applied to small, moving targets such as the coronary vessels remains to be determined.
b. Catheter Based Irradiation Studies
In contrast to the mixed results from external beam irradiation, numerous investigators have shown consistent benefit of endovascular irradiation on neointima formation. At least three groups have documented similar results in the porcine coronary model of restenosis, using 192 Ir at roughly comparable doses. Wiedermann and coworkers found suppression of neointima 4 weeks after angioplasty when 20 Gy was delivered at a radial depth of 1.5 mm just before arterial injury. 24 These same researchers demonstrated a persistence of this effect in arteries harvested at 6 months. 25 Similarly, our group at Emory demonstrated profound suppression of neointima using 192 Ir with a dose-response effect in vessels treated with 3.5, 7, and 14 Gy at a radial depth of 2 mm, and continued benefit at 6 months in arteries treated with 7 and 14 Gy. 26 The effect of endovascular irradiation in a repeat-injury model of restenosis has also been evaluated. 31 This model may be more analogous to clinical restenosis since a lesion is initially formed by the first balloon injury; 4 weeks later a second balloon angioplasty is applied, at which time brachytherapy is performed. In this model we observed that there was no morphologically apparent effect on the lesion created by the first injury, but the second 'wave' of hyperplasia was inhibited, resulting in a significantly smaller total intima. From theses animal studies there is no reason to believe that radiation will have any effect on an established stenosis but simply prevents an overexuberant healing response associated with balloon injury or stent implantation.
Although many different studies have shown endovascular brachytherapy to be effective in the short term in preventing renarrowing the results at 6 months have been decidedly mixed. Dr. Raizner and his colleagues from Baylor have shown that a significant component of late lumen loss following treatment to be due to thrombosis. This is felt to be due to delayed re-endothelialization and hopefully will be effectively treated by prolonged antiplatelet therapy.
c. Radioactive Stent Studies
Because a stent already deals with two of the major mechanisms of restenosis the idea of adding radiation to the fabric of the stent has considerable attractiveness. The first evaluation of a radioactive stent comes from Hehrlein and his colleagues from Heidelberg. They took stainless steel stents (Palmaz-Schatz stents) and made them radioactive in a nuclear reactor. 32 The stents were highly effective at inhibiting neointima formation but might be problematic for permanent implantation as some of the isotopes created have very long half-lives. Consequently, this same group of researchers and others investigated the effects of stents implanted with radioactive phosphorous ( 32 P) 33.34 Subsequently, this stent was tested in pig coronary arteries at various levels of radioactivity. Curiously, it was found that low-activity (0.15-to 0.5-µCi) and highactivity (3.0-to 23.0-µCi) stents inhibited neointima formation compared to control nonradioactive stents, but those of intermediate activity (1.0-µCi) had nearly twice as much neointima . 35 . The authors speculated that either delayed endothelialization or a stochastic effect on extracellular matrix production might be responsible for this puzzling finding.
Although the initial results appeared favorable for this form of therapy 6 month follow-up has shown poorer results in the irradiated animals compared to controls, with the highest dose groups doing worse than the lower dose groups. 36 It may be that the prolonged delivery of radiation in this application results in very different results that the acute application of radiation.
IV. Clinical Trials of Intracoronary Radiation Therapy
The benefits of intracoronary radiation therapy were just barely established before clinical investigation of this modality was initiated. In Tables 2, 3 
a. Clinical Trials of Catheter Based Gamma Irradiation
The first reported use of intracoronary radiation therapy to prevent restenosis in humans was from Condado and his colleagues in Caracas, Venezuela. 37 This study, The results of this trial have been updated at two years and the effect of the therapy appears to be durable although there were some cases with late renarrowing. There was no evident long-term injury. Subset analysis has been reported on these patients and although subject to criticism on the basis of limited patient numbers it was shown that larger vessels, vein grafts and reduced doses of radiation were all associated with a lack of benefit in this study. When the data was analyzed it was found that radiation was slightly less effective at reducing restenosis when one examined the stent and borders compared with the stent alone. As a result of this observation the investigators have made a conscious effort to irradiate beyond the margin of the stented segment. 
b. Clinical Trials of Catheter Based Beta Irradiation
Verin and his colleagues from Geneva reported the first feasibility study of beta radiation following angioplasty of stenotic lesions in native coronary vessels. 39 In this study 18 Gy was delivered to the luminal surface with a 29 mm 90 Y coil inserted into a closed end segmented balloon catheter following PTCA. Due to decay of the source (T1/2=64 hours) the treatment time was variable but averaged 6-7 minutes. Because of ischemia, fractionation of the dose was necessary in 4 of the original 15 patients studied.
At 6 month follow-up the restenosis rate was 6/15 or 40% with four patients (27%) required target lesion revascularization. The Late Loss Index was 50% which is what is within the range generally expected with PTCA alone. Because of the concern that this less than favorable result might have been related to the dose delivered to the vessel a dose-finding study has been initiated. This will test doses of 9, 18 and 32 Gy delivered to the luminal surface. Use of this same system was piloted by Waksman and his colleagues at the Washington Heart Center. Between May and October of 1998 49 patients were enrolled in this trial which had the same inclusion and exclusion criteria as (Table 7 ) No frank aneurysms were seen however. In July 1997 the BETACATH (Beta Energy to Address Coronary Atherosclerosis) Trial was opened as a follow-up to the BERT trial using the Novoste BETACATH system. This triple-masked study will enroll 1100 patients with restenosis or stenosis in native coronary vessels. Following initial balloon angioplasty those patients who achieve a stent-like result (< 30% residual stenosis and no major dissection) will be randomized to receive radiation or placebo. If the angioplasty result is not stent-like those patients will receive brachytherapy prior to stent implantation. The dose of radiation in the smaller vessels (2.5 to 3.3 mm) will be 14 Gy at 2 mm; in the larger vessels (3.3-4 mm) it will be 18 Gy. This increase in dose is related to the observed reduced efficacy in larger vessels observed in the BERT Trial.
The radiation is administered prior to the stent implantation to circumvent any problems associated with shielding by the stent. Efficacy in this trial will be based on the need for target vessel revascularization at 8 months following intervention. Novoste Corporation has also embarked on a randomized study called the START Trial to test whether beta radiation is a useful adjunct in the management of in-stent restenosis.
Guidant Corporation has developed an afterloading system for vascular brachytherapy using a 27 mm long 32 P wire source which is delivered within a helical centering balloon. The initial feasibility study of this device is entitled the PREVENT (Proliferation Reduction with Vascular Energy Trial) Trial which randomized patients between three different doses of radiation (16, 20 and 24 Gy at 1 mm from the balloon/lumen interface) following PTCA or stenting. 6 month angiographic follow-up on 66 of the 72 patients enrolled on the study reveals a marked treatment effect has revealed a marked treatment effect. Only 6% of the irradiated arm had restenosis within the treated area compared to 33% of controls. In this trial a considerable number of patients had restenosis adjacent to the treatment zone suggesting the need for a longer source or the possibility that the ballloon centering catheter was creating edge effect.
patients whose disease. An additional feasibility study of a partially shielded beta source (186Re) has been developed by Navius and Endosonics Corporation. This device is intended to allow a more homogeneous dose to be delivered to the vessel wall. 
c. Clinical Trials of Radioactive Stents
The first trial of a 32 P impregnated radioactive Palmaz-Schatz stent was undertaken under the direction of Dr. T. Fischell and colleagues and was entitled IRIS (Isostent for Restenosis Intervention Study). This study enrolled 30 patients with denovo or restenotic lesions of native coronary vessels who were implanted with a stent of mean activity of 0.69 µCi (range 0.5-1.0 µCi). The procedural success rate was 100% but the angiographic restenosis rate at 6 months was 31%, a figure higher than generally expected for patients with these type lesions implanted with non-radioactive stents. Late loss was 0.94 mm for de-novo lesions and 0.70 mm for restenotic lesions suggesting somewhat better results for patients with restenosis. One possible interpretation of this result is that restenotic lesions may be more effectively treated than de novo lesions because the cells that lead to renarrowing following stenting are closer to the luminal surface and the stent. It may be that the very limited dose delivered to the adventitia with a radioactive stent is inadequate for de novo lesions. Results of studies with stents of higher activities (3 and 6 µCi) are pending. The P-S stent has a very irregular structure and is in no way optimal as a carrier to deliver a homogenous dose of radiation to the vessel wall. A new stent (BX Stent) has been developed which may be more optimal for delivering radiation and studies using this stent are currently underway.
V. Conclusions:
Initial feasibility studies and small randomized studies 
